Compare Abbott Laboratories (ABT) vs Matson Inc (MATX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Matson Inc — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Matson Inc trades at $201.49 (market cap $6.01B). The key difference: Abbott Laboratories is far larger — about 27.8× Matson Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MATX | |
|---|---|---|
Market Cap | $166.94B | $6.01B |
Sector | Health | Technology |
52-Week High | $136.62 | $204.53 |
52-Week Low | $82.57 | $88.05 |
Enterprise Value | $193.69B | $6.61B |
Dividend Yield | 2.63% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Matson (MATX) trades at $204.53, up 0.49% with strong technical momentum near resistance at $206. The stock shows robust fundamentals with consistent earnings beats, a 12.92% net margin, and shareholder-friendly actions including dividend increases and share buybacks. Recent news highlights the company's niche Pacific shipping advantages and operational efficiency gains.
Outlook remains positive given analyst consensus (64% buy ratings) and strong profitability metrics, though risks include shipping rate volatility and macroeconomic sensitivity. The current valuation at 15.17x P/E appears reasonable for a company with double-digit ROE and dividend growth, positioning MATX as a quality mid-cap transportation play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
